1406P Interim results of a phase II trial of sacituzumab govitecan (SG) in patients (Pts) with metastatic castration resistant prostate cancer (mCRPC) progressing on androgen receptor signaling inhibitors (ARSI)
Jessica D. Lang(Translational Genomics Research Institute), Christos E. Kyriakopoulos(Dana-Farber Cancer Institute), Ana M. Molina(Cornell University), Hamid Emamekhoo(University of Wisconsin Carbone Cancer Center), D.M. Nanus(Cornell University), Susan F. Slovin(Cornell University), Jamie M. Sperger(University of Wisconsin–Madison), Han Xiao(Memorial Sloan Kettering Cancer Center), Wassim Abida(Memorial Sloan Kettering Cancer Center), Scott M. Dehm(University of Minnesota), Karen A. Autio(Memorial Sloan Kettering Cancer Center), Dana E. Rathkopf(Memorial Sloan Kettering Cancer Center), Jens C. Eickhoff(University of Wisconsin–Madison), Scott T. Tagawa(Cornell University)
Cited by 8
Related Papers
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
OncoKB: A Precision Oncology Knowledge Base
|JCO Precision Oncology|2017|2.7k
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
|Journal of Clinical Oncology|2016|1.6k